Stock Analysis
Data Source: SEC EDGAR 13F
Updated Hourly

Igc Pharma Inc (IGC)

34 + Investors. Track Smart Money conviction in IGC. See who's accumulating, reducing, or initiating positions.

Current Price
-- USD
Analyst Target
-- (0 analysts)
Upside
0.00%
Net Flow Q/Q
↑ +4
Streak
1Q ▲
Buyers last Q
59%

Smart Money Signals — IGC

Based on 34 hedge funds · latest filing: 2026 Q1 · updated quarterly

📈

Buying streak — 1 quarter in a row

last 6Q
For 1 consecutive quarter, more hedge funds added IGC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.
🏔️

At the ownership peak (97% of max)

97% of all-time peak
34 hedge funds hold IGC right now — the highest count in 3.0 years. When ownership is this concentrated, any bad news can trigger a chain reaction: one big fund sells, others follow. This is a classic 'crowded trade' — high popularity doesn't equal safety.
🚀

Fast accumulation — +48% more funds vs a year ago

fund count last 6Q
+11 new funds entered over the past year (+48% YoY). That's a rapid rush of institutional money. Fast accumulation often signals a major thesis — but it also means the stock could fall quickly if that thesis breaks.
🟡

Slight buying edge — 59% buying

16 buying11 selling
Last quarter: 16 funds bought or added vs 11 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.
📈

More new buyers each quarter (+6 vs last Q)

new funds entering per quarter
Funds opening a new IGC position: 7 → 10 → 4 → 10. A growing influx of new institutional buyers means the asset is still gathering momentum — the consensus hasn't fully saturated yet.
🔒

47% of holders stayed for 2+ years

■ 47% conviction (2yr+) ■ 12% medium ■ 41% new
16 out of 34 hedge funds have held IGC for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.
📊

Peak discovery — momentum slowing

1 → 7 → 10 → 4 → 10 new funds/Q
New funds entering each quarter: 7 → 10 → 4 → 10. IGC is well-known in the hedge fund world, but fresh entries are gradually declining. The explosive phase of institutional discovery is likely behind us.
🏛️

Veteran-anchored — 50% veterans vs 41% newcomers

■ 50% veterans ■ 9% 1-2yr ■ 41% new
Entry-cohort mix of 34 holders: 17 (50%) are 2+ year veterans, 3 entered 1–2 years ago, and 14 (41%) joined within the past year. A veteran-weighted cap table skews toward institutional memory over fresh momentum.
✅

Strong quality — 38% AUM from major funds

38% from top-100 AUM funds
8 of 34 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.
4.1
out of 10
Moderate Exit Risk
Exit risk score 4.1/10 — some crowding factors present, but no critical concentration. Watch ownership trend over the next 1–2 quarters for direction.

Methodology note: these Smart Money cards use consecutive 13F disclosure snapshots, not trade-by-trade execution data. "Buying", "selling", "new holders", and "trimmed" refer to quarter-over-quarter changes in reported holders, aggregate shares, or disclosed position values between filings. They are useful for ownership regime analysis and crowding, but they do not imply exact trade timing on the filing date.

Institutional Sentiment Summary — IGC

In 2026 Q1, 16 hedge funds were net buyers of IGC (10 opened a new position, 6 added to an existing one), while 11 reduced or exited (5 trimmed, 6 sold completely) — a 59% buyer ratio, indicating a slight buying edge. 38% of total institutional value in IGC is held by top-100 AUM funds, reflecting strong institutional quality. Net fund flow last quarter: +4 funds (more new holders than closures). Total institutional holders: 34.

Hedge Fund Ownership: IGC

How many hedge funds hold IGC — quarterly history vs. share price
Quarterly hedge fund ownership of IGC vs. share price

Market Analysis: IGC

Analyst Price Targets

Avg. Price Target
--

Analyst Recommendations

Stock Performance

Real-time

Company Profile: IGC

-- --

Institutional ownership data sourced from SEC EDGAR Form 13F-HR filings.

Is It Too Late to Buy Igc Pharma Inc (IGC) Based on Hedge Fund 13F Filings?

Signal Freshness measures how much IGC has moved relative to its sector benchmark (XLV) since the 2026 Q1 13F filing. A stock that has barely outrun its sector is still a relatively fresh entry point — the fund's thesis has not yet been priced in by the broader market.

Since Quarter End March 31, 2026 · 78d ago
IGC
+6.0%
XLV
+3.8%

IGC outperformed XLV by +2.2% since March 31, 2026.

Since 13F Filing Date May 15, 2026 · 33d ago
IGC
-3.9%
XLV
+4.9%

Since the filing became public, IGC outperformed XLV by -8.8% .

Interpretation: The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference. Learn more →

Smart Money Signal ?
Limited Smart Money Interest

No strong consensus or elite conviction detected among institutional holders.

4 top-rated funds 0 high-conviction
Consensus
3.0
/ 10
breadth
×
Elite
0.0
/ 10
conviction
Hedge Fund Positioning: IGC
34 + Investors

Track Smart Money conviction in IGC. See who's accumulating, reducing, or initiating positions.

Metric All 13F Filers (2026 Q1) Prior (2025 Q4) Change
Funds Holding 34 30 13.33%
13F Shares 4M 5M -10.64%
Total Value $1M $1M -16.91%
New Positions 10 4 +6
Increased Positions 6 5 +1
Closed Positions 6 9 -3
Reduced Positions 5 5 -
Total Calls 0 0 -
Total Puts 0 0 -
PUT/CALL Ratio 0.0 0.0 Bullish

Statistics: IGC

View More

Valuation Measures Data as of: --

Market Cap --
Enterprise Value --
Trailing P/E --
Forward P/E --
PEG Ratio (5yr expected) --
Price/Sales (ttm) --
Price/Book (mrq) --
Enterprise Value/Revenue --
Enterprise Value/EBITDA --
Beta (5Y Monthly) --
Short Ratio (Days to Cover) --
Short % of Float --

Financial Highlights

Profitability
Profit Margin --
Return on Assets (ttm) --
Return on Equity (ttm) --
Income Statement & Cash Flow
Revenue (ttm) --
Net Income Avi to Common (ttm) --
Diluted EPS (ttm) --
Total Cash (mrq) --
Total Debt/Equity (mrq) --
Levered Free Cash Flow (ttm) --

Institutional Holders (2026 Q1)

34 + investors

Explore institutional interest and hedge fund ownership dynamics. Analyze portfolio weights, new positions, and conviction trends in IGC. Verified SEC 13F-HR filings.

QUARTER:
Top 25 IGC holders by conviction (% of portfolio weight) — 2026 Q1 · Source: SEC Form 13F
# Investor % of Portfolio Shares Mkt Value
1 Lawood & Co 0.02% 75,000 $20K
2 T3 Companies, LLC 0.01% 20,000 $5K
3 Trask Adam Roland 0.00% 5,000 $1K
4 Dearborn Partners LLC 0.00% 59,401 $16K
5 Schneider Downs Wealth Management Advisors, LP 0.00% 10,000 $3K
6 XTX Topco Ltd 0.00% 50,648 $13K
7 Renaissance Technologies LLC 0.00% 483,975 $127K
8 Tower Research Capital LLC (TRC) 0.00% 21,049 $6K
9 Wealthcare Advisory Partners LLC 0.00% 10,000 $3K
10 Caitlin John, LLC 0.00% 200 —
11 Vanguard Fiduciary Trust Co 0.00% 415,888 $109K
12 Geneos Wealth Management Inc. 0.00% 3,000 —
13 Hurley Capital, LLC 0.00% 100 —
14 Truist Financial Corp 0.00% 36,667 $10K
15 Commonwealth Equity Services, LLC 0.00% 33,848 $9K
16 DHJJ Financial Advisors, Ltd. 0.00% 80 —
17 Vanguard Capital Management LLC 0.00% 718,436 $189K
18 Fisher Asset Management, LLC 0.00% 43,400 $11K
19 Susquehanna International Group, LLP 0.00% 122,595 $32K
20 Napier Financial, LLC 0.00% 58 —
21 BlackRock, Inc. 0.00% 703,798 $185K
22 HighTower Advisors, LLC 0.00% 10,000 $3K
23 Goldman Sachs Group Inc 0.00% 65,541 $17K
24 Group One Trading LLC 0.00% 3,762 —
25 Cwm, LLC 0.00% 1,000 —
Investor Ownership
History 		% of Portfolio Prev % Rank Conviction Avg Buy Price 13F Score™ 3Y / 7Y Sell Timing Shares Mkt Value Change Change % Source Quarter Filed

Frequently Asked Questions — Igc Pharma Inc (IGC)

What does the Smart Money Trend signal show for IGC?

Buying streak — 1 quarter in a row: For 1 consecutive quarter, more hedge funds added IGC than sold it. That's a consistent pattern of professional buying — not a one-time trade. When institutions keep buying quarter after quarter, it usually means they see a multi-year opportunity, not just a short-term momentum flip.

What is the institutional breadth score for IGC?

Slight buying edge — 59% buying: Last quarter: 16 funds bought or added vs 11 that reduced or exited. It's nearly a 50/50 split — some institutions are convinced, others are taking profits. This mixed picture is normal near price highs.

What is the fund quality score for IGC holders?

Strong quality — 38% AUM from major funds: 8 of 34 holders rank in the top 100 by AUM, accounting for 38% of total institutional value held. A meaningful share of the ownership value comes from the most well-resourced institutions.

How long have hedge funds held IGC?

47% of holders stayed for 2+ years: 16 out of 34 hedge funds have held IGC for over 2 years without selling. Long-term investors are generally harder to shake out during market stress, creating a stable ownership base that limits the risk of sudden capitulation.

Is it too late to buy Igc Pharma Inc (IGC) following the 2026 Q1 hedge fund 13F filings?

As of today, IGC has moved -3.9% since the 2026 Q1 13F filing date (May 15, 2026), compared to +4.9% for the XLV sector ETF — an outperformance of -8.8%. Since the quarter end (March 31, 2026), IGC has gained +6.0% vs +3.8% for XLV. The stock is tracking its sector benchmark closely. The signal remains fresh and the entry point is still near the fund's implied reference.

Where does this institutional ownership data come from?

All holdings data is sourced from SEC Form 13F filings, which institutional investment managers with over $100 million in assets are required to submit quarterly. Data is parsed directly from SEC EDGAR.

Disclaimer: The information on this page is for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Institutional holdings data is sourced from SEC Form 13F filings and reflects positions as of the filing date. Past performance of any fund or portfolio is not indicative of future results. 13Foresight is not a registered investment adviser. Always conduct your own due diligence before making investment decisions.

Full history →